Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1989 1
1992 1
2003 1
2004 2
2010 1
2011 2
2012 2
2014 2
2015 1
2017 2
2018 2
2019 1
2020 1
2021 1
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Systemic Therapy for Melanoma: ASCO Guideline Update.
Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J. Seth R, et al. J Clin Oncol. 2023 Oct 20;41(30):4794-4820. doi: 10.1200/JCO.23.01136. Epub 2023 Aug 14. J Clin Oncol. 2023. PMID: 37579248
UPDATED RECOMMENDATIONS: Neoadjuvant pembrolizumab was newly recommended for patients with resectable stage IIIB to IV cutaneous melanoma. For patients with resected cutaneous melanoma, adjuvant nivolumab or pembrolizumab was newly recommended for stag …
UPDATED RECOMMENDATIONS: Neoadjuvant pembrolizumab was newly recommended for patients with resectable stage IIIB to IV cutaneous m …
In-transit metastatic cutaneous melanoma: current management and future directions.
Patel A, Carr MJ, Sun J, Zager JS. Patel A, et al. Clin Exp Metastasis. 2022 Feb;39(1):201-211. doi: 10.1007/s10585-021-10100-3. Epub 2021 May 17. Clin Exp Metastasis. 2022. PMID: 33999365 Review.
After full body radiographic staging is performed to rule out metastatic disease, curative therapy may be performed through surgical excision, intraarterial regional perfusion and infusion therapies, intralesional injections, systemic therapies or vari …
After full body radiographic staging is performed to rule out metastatic disease, curative therapy may be performed through su …
Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T, Meraz-Torres F, Garbe C. Amaral T, et al. Expert Opin Biol Ther. 2017 Dec;17(12):1523-1538. doi: 10.1080/14712598.2017.1378640. Epub 2017 Sep 17. Expert Opin Biol Ther. 2017. PMID: 28891339 Review.
Around 45% of the patients diagnosed with metastatic cutaneous melanoma harbor a BRAFV600 mutation and derive benefit from combined targeted therapy with MAPK pathway inhibitors. ...Areas covered: In this review, the authors discuss the late evidence f …
Around 45% of the patients diagnosed with metastatic cutaneous melanoma harbor a BRAFV600 mutation and derive benefit f …
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Pavlick AC, Ariyan CE, Buchbinder EI, Davar D, Gibney GT, Hamid O, Hieken TJ, Izar B, Johnson DB, Kulkarni RP, Luke JJ, Mitchell TC, Mooradian MJ, Rubin KM, Salama AK, Shirai K, Taube JM, Tawbi HA, Tolley JK, Valdueza C, Weiss SA, Wong MK, Sullivan RJ. Pavlick AC, et al. J Immunother Cancer. 2023 Oct;11(10):e006947. doi: 10.1136/jitc-2023-006947. J Immunother Cancer. 2023. PMID: 37852736 Free PMC article.
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. ...Other immunotherapy strategie …
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ag …
Ocular Inflammatory Complications of Treatment for Metastatic Melanoma.
Philip AM, Anesi SD, Foster CS, Chang P. Philip AM, et al. Ocul Immunol Inflamm. 2023 Oct;31(8):1669-1673. doi: 10.1080/09273948.2022.2098147. Epub 2022 Aug 1. Ocul Immunol Inflamm. 2023. PMID: 35914291
PURPOSE: To characterize various ocular inflammatory complications arising from metastatic cutaneous melanoma therapies and their management. METHODS: Retrospective case series of patients who were referred to a tertiary uveitis practice for ophthalmic …
PURPOSE: To characterize various ocular inflammatory complications arising from metastatic cutaneous melanoma therap …
Treatment of acral and mucosal melanoma: Current and emerging targeted therapies.
Zhang J, Tian H, Mao L, Si L. Zhang J, et al. Crit Rev Oncol Hematol. 2024 Jan;193:104221. doi: 10.1016/j.critrevonc.2023.104221. Epub 2023 Nov 29. Crit Rev Oncol Hematol. 2024. PMID: 38036156 Review.
Targeted therapies revolutionized the management of patients with advanced and metastatic cutaneous melanoma. However, despite recent advances in the understanding of the molecular drivers of melanoma and its treatment with targeted therapies …
Targeted therapies revolutionized the management of patients with advanced and metastatic cutaneous melanoma. Ho …
Management of metastatic cutaneous melanoma.
Buzaid AC. Buzaid AC. Oncology (Williston Park). 2004 Oct;18(11):1443-50; discussion 1457-9. Oncology (Williston Park). 2004. PMID: 15609471 Free article. Review.
The results of treatment for metastatic melanoma remain disappointing. Single-agent chemotherapy produces response rates ranging from 8% to 15%, and combination chemotherapy, from 10% to 30%. ...
The results of treatment for metastatic melanoma remain disappointing. Single-agent chemotherapy produces response rates rangi …
Use of circulating tumoral DNA to guide treatment for metastatic melanoma.
Herbreteau G, Charpentier S, Vallée A, Denis MG. Herbreteau G, et al. Pharmacogenomics. 2019 Dec;20(18):1259-1270. doi: 10.2217/pgs-2019-0097. Epub 2019 Oct 9. Pharmacogenomics. 2019. PMID: 31596166 Review.
The management of metastatic cutaneous melanoma is conditioned by the identification of BRAF-activating mutations in tumor DNA. ...Circulating tumor DNA (ctDNA), released into blood by cancer cells, is a good alternative to tissue sampling. ctDNA is not subje …
The management of metastatic cutaneous melanoma is conditioned by the identification of BRAF-activating mutations in tu …
Immunotherapy in sinonasal melanoma: treatment patterns and outcomes compared to cutaneous melanoma.
Klebaner D, Saddawi-Konefka R, Finegersh A, Yan CH, Califano JA 3rd, London NR, Deconde AS, Faraji F. Klebaner D, et al. Int Forum Allergy Rhinol. 2020 Sep;10(9):1087-1095. doi: 10.1002/alr.22628. Epub 2020 Jul 5. Int Forum Allergy Rhinol. 2020. PMID: 32623838
BACKGROUND: Although treatment with checkpoint blockade is now accepted as standard of care for cutaneous melanoma, few studies have investigated its role in sinonasal melanoma (SNM). ...Regimens including immunotherapy were associated with improved ov …
BACKGROUND: Although treatment with checkpoint blockade is now accepted as standard of care for cutaneous melanoma, few …
Systematic review: surgery for patients with metastatic melanoma during active treatment with ipilimumab.
Baker JJ, Stitzenberg KB, Collichio FA, Meyers MO, Ollila DW. Baker JJ, et al. Am Surg. 2014 Aug;80(8):805-10. Am Surg. 2014. PMID: 25105403 Review.
Studies of ipilimumab have shown improved overall survival in patients with metastatic cutaneous melanoma. As a result, use of ipilimumab in patients with Stage IV melanoma is rapidly increasing. ...We performed a systematic review of the literature us …
Studies of ipilimumab have shown improved overall survival in patients with metastatic cutaneous melanoma. As a result, …
25 results